Weekly CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings on May 16, 2018

May 16, 2018 - By Alice Fox

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

A total of 8 analysts rate CymaBay Therapeutics (NASDAQ:CBAY) as follows: 8 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:CBAY) has 16 ratings reports on May 16, 2018 according to StockzIntelligence. On Wednesday, January 31 the company was maintained by Piper Jaffray. On Wednesday, January 24 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by H.C. Wainwright. On Monday, April 16 the firm earned “Buy” rating by Roth Capital. On Wednesday, January 10 the stock has “Buy” rating by Oppenheimer. On Wednesday, March 21 the firm has “Buy” rating given by Oppenheimer. On Wednesday, May 9 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given by Oppenheimer. On Wednesday, March 28 the firm earned “Buy” rating by Leerink Swann. In Friday, March 16 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Wednesday, April 11 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given by Leerink Swann. On Friday, March 16 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given by SunTrust. Listed here are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) PTs and latest ratings.

09/05/2018 Broker: Oppenheimer Rating: Buy New Target: $20.0000 Maintain
16/04/2018 Broker: Roth Capital Rating: Buy New Target: $27.0000 Maintain
11/04/2018 Broker: Leerink Swann Rating: Buy New Target: $20.0000 Maintain
11/04/2018 Broker: Evercore Rating: Buy
28/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18.0000 Initiate
28/03/2018 Broker: Leerink Swann Rating: Buy New Target: $16.0000 Maintain
21/03/2018 Broker: Oppenheimer Rating: Buy Maintain
16/03/2018 Broker: SunTrust Rating: Buy New Target: $19.0 Maintain
16/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $16.0 Maintain

Ticker’s shares touched $12.21 during the last trading session after 3.83% change.CymaBay Therapeutics, Inc. is uptrending after having risen 197.77% since May 16, 2017. CBAY has 1.07M volume or 0.83% up from normal. The stock outperformed the S&P 500 by 186.22%.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases.The firm is worth $717.57 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout.Currently it has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

For more CymaBay Therapeutics, Inc. (NASDAQ:CBAY) news published briefly go to: Nasdaq.com, Seekingalpha.com, Globenewswire.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta …” published on April 20, 2018, “CymaBay Makes Progress With Seladelpar” on April 30, 2018, “CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8” with a publish date: May 01, 2018, “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” and the last “CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic …” with publication date: May 08, 2018.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: